Data Engineering plays a key role in insitro’s approach to rethinking drug development. Our team is responsible for ensuring our biological data factory’s robots and instruments produce high quality data, optimizing storage, queries, and analysis of petabytes of scientific experimental results, and building the infrastructure to train powerful models that solve key problems in the drug development process. You will work closely with a cross-functional team of scientists, bioengineers, and data scientists to identify areas where data engineering can make a difference, by developing data architectures and systems on cutting edge, high throughput platforms that enable our scientists to be maximally productive. You will design, implement, and deploy novel methods that use a broad spectrum of data engineering approaches, including techniques at the forefront of the field. You will work as part of a team to rigorously design our data platform, identify key architectural performance improvements and support ongoing discovery and automation platforms.
You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding, but yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH and, in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www. insitro.com.
Your application was submitted successfully.